Tonix Pharmaceuticals Holding Corp.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $13.1M | $10.1M | $7.8M | — | — |
| Cost of revenue | $6.6M | $7.8M | $4.7M | — | — |
| Selling, general & administrative | $87.7M | $40.1M | $34.8M | $30.2M | — |
| Research and development | $44.5M | $40.0M | $86.7M | $81.9M | $68.8M |
| Operating income | -$125.7M | -$136.7M | -$118.4M | -$112.1M | -$92.3M |
| Interest expense | $89,000 | $1.2M | — | — | — |
| Net income | -$124.0M | -$130.0M | -$116.7M | -$110.2M | -$92.3M |
| Balance Sheet | |||||
| Cash and equivalents | $207.6M | $98.8M | $24.9M | $120.2M | $178.7M |
| Current assets | $228.9M | $119.0M | $47.8M | $130.8M | $189.0M |
| Total assets | $277.2M | $162.9M | $154.5M | $225.7M | $240.9M |
| Current liabilities | $30.8M | $18.3M | $18.9M | $18.2M | $21.7M |
| Total liabilities | $32.0M | $23.3M | $48.9M | $18.5M | $22.2M |
| Total debt | — | $5.8M | $8.7M | — | — |
| Stockholders' equity | $245.2M | $139.6M | $105.5M | $207.2M | $218.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$99.8M | -$60.9M | -$102.0M | -$98.1M | -$75.6M |
| Depreciation and amortization | $1.9M | $3.4M | $4.3M | $1.3M | $50,000 |
| Stock-based compensation | $6.0M | $4.8M | $9.3M | $10.9M | $7.9M |
| Capital expenditure | $3.4M | $120,000 | $7.9M | $48.1M | $35.3M |
| Free cash flow | -$103.2M | -$61.0M | -$109.9M | -$146.2M | -$110.9M |
| Share repurchases | $13.8M | — | $14.0M | — | — |
| Impairments | — | $59.0M | — | — | — |
Shares outstanding 15.9M · Free float 94.1%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.